Keloid transcriptomics reveal heterogeneity in fibroblast subtype enrichment, gene expression, and immune cell responses

Skin is our body's first line of defense, a resilient barrier that repairs itself when broken. When a cut heals, the body sends a team of specialized cells to close the gap, laying down new fibers to hold everything together. Usually, this process stops once the wound is sealed, leaving behind a flat, pale scar. But for some people, the repair crew never gets the signal to stop. Instead of settling down, these cells keep building, piling up thick, raised, and often painful tissue that grows far beyond the original injury. This condition, known as a keloid, is more than just a cosmetic issue; it can itch, ache, and refuse to go away, even after surgery. While anyone can develop these scars, they appear much more frequently and aggressively in people with darker skin tones, particularly those of African descent. Yet, for a long time, the molecular secrets behind why this happens in these specific populations have remained largely hidden, leaving doctors to treat a complex biological puzzle with limited information.

To solve this puzzle, a team of researchers at Henry Ford Health in Detroit turned their attention to the very cells that build these scars. They collected tissue samples from fourteen patients who were undergoing surgery to remove keloids from their heads or necks. For each patient, they took two samples: one from the overgrown scar tissue itself, and another from the healthy skin right next to it. This side-by-side comparison allowed them to see exactly what was different in the diseased tissue. The researchers focused on two main groups of cells: fibroblasts, which are the construction workers that lay down collagen and other structural materials, and immune cells, which act as the body's security force, managing inflammation and healing. By reading the genetic instructions inside these tissues, the team could count how many of each cell type were present and see how they were behaving.

What they found was a landscape of distinct differences. In the healthy skin, the cellular mix was balanced, but in the keloid tissue, the balance had tipped. The scar tissue was crowded with specific types of fibroblasts that are known for being highly active and prone to overproduction. These included "mesenchymal" cells, which have a high potential to turn into other types of connective tissue, and "secretory-reticular" cells, which are busy churning out proteins. Alongside these overactive builders, the immune system had also shifted its strategy. The scar tissue was filled with activated versions of mast cells and natural killer cells, as well as specific types of macrophages that are known to encourage tissue growth rather than just cleaning up debris. Conversely, the healthy skin samples contained higher levels of resting immune cells and other types that were notably absent or reduced in the scars. This suggested that the keloid is not just a mass of overgrown skin, but a unique environment where specific cell types are recruited and activated in a way that normal skin does not experience.

The researchers then looked deeper to see how these different cell groups were talking to each other. In healthy skin, certain fibroblasts and immune cells tend to work in a coordinated rhythm, but in the keloid, this relationship had changed. The team discovered that the usual connections between these cells were often broken or altered. For instance, in the scar tissue, the link between certain fibroblasts and immune cells was much weaker than in the healthy skin, as if the two groups had stopped listening to one another. However, there were also new, strong partnerships that formed only in the keloid. One striking example was a tight association between activated mast cells and the overactive mesenchymal fibroblasts, suggesting that these two groups might be fueling each other's growth in a cycle that keeps the scar expanding. Another unique connection appeared between activated natural killer cells and the secretory-reticular fibroblasts, a pairing that was not seen in the normal tissue. These findings indicate that the keloid is driven by a specific, localized conversation between cells that goes wrong, creating a self-sustaining loop of growth.

Finally, the team asked what genes were being turned on or off to drive this chaotic behavior. Because the mix of cells was so different between the scar and the healthy skin, they had to be careful not to mistake a change in cell numbers for a change in gene activity. By adjusting their analysis to account for the different cell populations, they isolated the true genetic signals. They found that a gene called MIR31HG was turned on to a much higher level in the keloids, while another gene, NR4A2, was significantly turned down. MIR31HG is known to influence how cells divide and grow, and its high levels in the scar suggest it plays a major role in the uncontrolled expansion of the tissue. The drop in NR4A2, a gene that helps regulate inflammation and cell growth, might remove a natural brake that usually stops the healing process. The study also highlighted that the biological pathways active in these scars looked surprisingly similar to those seen in cancer, with signals for cell growth and inflammation firing constantly, even though the scar itself is not cancerous.

This research provides a clearer map of what is happening inside a keloid, moving beyond the idea of a simple overgrowth to reveal a complex ecosystem of specific cells and genes working together in a broken pattern. By focusing on a cohort that included a majority of African American patients, the study addresses a gap in previous research that often overlooked this high-risk group. The findings suggest that the key to treating these stubborn scars may lie in disrupting the specific partnerships between the overactive builders and the immune cells, or in targeting the genetic switches that keep them running. While the study does not offer a new treatment yet, it lays the essential groundwork for understanding the unique biology of keloids, pointing the way toward therapies that could one day stop the repair crew from building forever.